EasyM

Heading to EHA? So are we!

We're excited to be presenting two posters at EHA 2026:

📌 PF833 | Poster Session 1
Comparison of Clonotypic Peptide (EasyM) and Intact Immunoglobulin (Exent) Monitoring
🔗https://library.ehaweb.org/eha/2026/eha-2026/4207821/jessie.zhao.comparison.of.clonotypic.peptide.28easym29.and.intact.immunoglobulin.html

📌 PS1904 | Poster Session 2
Evaluation of Early M-Protein Kinetics Post-CAR T-Cell Therapy with EasyM
🔗https://library.ehaweb.org/eha/2026/eha-2026/4208455/ravi.vij.evaluation.of.early.m-protein.kinetics.post-car.t.cell.therapy.with.html

If you're attending EHA, we'd love to connect. Send us a DM or stop by our posters in Hall A to chat about EasyM, MRD monitoring, and multiple myeloma research.

Today is World Blood Cancer Day ❤️

Did you know? Every 27 seconds, someone around the world is diagnosed with a blood cancer.

At EasyM, we recognize the importance of awareness, early detection, and accessible healthcare in helping patients receive timely care and support. Today, we stand with patients, families, caregivers, and healthcare professionals in the fight against myeloma and other blood cancers.

Together, through awareness and innovation, we can help create a healthier future for everyone.

The EasyM Team is Heading to ASCO 2026! ✈️💼

The countdown is on! The EasyM team is packing our bags and heading to Chicago for the ASCO Annual Meeting!

We are incredibly excited to immerse ourselves in the groundbreaking science, clinical breakthroughs, and vital discussions shaping the future of cancer care worldwide. Above all, we want to connect with the incredible community of clinicians, researchers, innovators, and advocates working to improve patient outcomes.

If you are attending in person, let's make time to connect! We would love to discuss how we can collaborate, share insights, and continue driving meaningful progress in Multiple Myeloma.

📅 When: May 29 - June 2, 2026

📍 Where: McCormick Place | Chicago, IL

👇 Attending ? Drop a comment below, or send us a DM to set up a meet-up! See you in Chicago! 🤝

The Evolving Role of MRD in Multiple Myeloma Care 🎯

A recent review by Landgren et al. (2026) describes how Minimal Residual Disease (MRD) is transitioning from a research metric into a clinical tool for informing treatment strategies and drug approvals.

Three Key Observations:

1. Regulatory Milestones: The FDA has recognized MRD as an "early endpoint" for accelerated approval. This regulatory shift aims to bring promising therapies to patients faster by evaluating disease clearance at the molecular level (10-5 or 10-6).

2. Response Adapted Strategies: Data from clinical trials, including PERSEUS, MIDAS, and ADVANCE, demonstrate the feasibility of using MRD to personalize care. Research indicates that for some patients, sustained MRD negativity may allow for discussions regarding treatment de-escalation (such as modifying maintenance or transplant timing), while persistent MRD may suggest a need for intensified therapy.

3. Advances in Monitoring: The field is exploring high-sensitivity blood-based MRD tools (such as mass spectrometry and ctDNA). These emerging "global" tests aim to provide non-invasive monitoring of the entire body.

The Bottom Line: We are moving toward personalized care and MRD assessment could help provide a "compass" that can help your healthcare team tailor treatment based on your specific response.

📖 Read the full scientific review: https://doi.org/10.1053/j.seminhematol.2026.01.002

MRD Response: Why Durability Matters More Than Speed

📃New data from the NICHE study (1,048 patients) suggests that when it comes to Minimal Residual Disease (MRD), the speed of your response may be less important than its durability.

Key Findings:

-The "Late + Durable" Advantage: Patients who took longer than 6 months to reach their best response often had better long-term survival than "early responders."
- Duration is Key: Maintaining a stable response for 36+ months was a stronger predictor of success than hitting "MRD Negative" early on.
- Stable is Successful: Even patients who remained "persistent MRD positive" saw excellent outcomes if their disease burden stayed low and stable over time.
- Overcoming High Risk: A durable response helped "cancel out" adverse features, such as high-risk cytogenetics or skipping a transplant.

This study highlights the value of longitudinal monitoring, tracking your personal trends over years, not just months. Read the full article here: https://onlinelibrary.wiley.com/doi/10.1002/ijc.70465

Follow along for the latest updates in MRD research 📣

Standard vs. MRD Monitoring: A Deep Dive into M-Protein Testing 🩸

Standard Laboratory Monitoring (SPEP/IFE):

- Clinical standards used to measure monoclonal protein (M-protein) levels.
- These tests analyze the overall distribution of proteins to identify an M-protein "spike."
- Effective at identifying high levels of disease, these tests have a defined "Limit of Detection." Once protein levels decrease below this threshold, they may be unable to distinguish the M-protein from normal, healthy proteins.
- A "not detected" result indicates a significant clinical response, though it does not always confirm the absence of disease at a molecular level.

Minimal Residual Disease Monitoring (Mass Spectrometry):

- Used in specific clinical contexts to achieve higher levels of sensitivity.
- This approach identifies the unique "fingerprint" of a patient’s specific M-protein.
- By focusing on this specific sequence, the laboratory can distinguish the M-protein from background proteins, allowing for the identification of residual disease even when levels are below the detection limit of conventional methods.

Follow along to learn more about MRD in MM 💡

Understanding Blood Based MRD Monitoring in Multiple Myeloma 🩸


Check out this HealthTree for Multiple Myeloma Foundation webinar recording featuring Dr. Benjamin Derman 👇

Dr. Derman provides an excellent breakdown of blood based minimal residual disease (MRD) testing in multiple myeloma (MM). Watch the recording to get a better understanding of how these non-invasive alternatives are evolving in MM care.

Webinar content:
- A clear explanation of how blood based testing works to monitor MRD in MM.
- Insights into the role of these tools in assessing treatment response and molecular clearance.
- Practical guidance on how to discuss these tools with your healthcare team.

Link: https://healthtree.org/myeloma/community/events/apr26-myeloma-mrd-testing?utm_source=intercom&utm_medium=email&utm_campaign=followuprecording&utm_content=general

Three Pillars to MRD Monitoring in Myeloma 💪

Clinicians use three complementary methods to track disease response:

1. Mass Spectrometry: Tracks the unique M-protein "fingerprint" in the blood.

2. NGS/NGF: Uses bone marrow biopsies to directly count residual cancer cells.

3. PET/MRI: Uses advanced imaging to visualize where myeloma is active or located in the body.

Why it matters: These approaches are often used together to provide a holistic view of the disease.

Talk to your healthcare team about which monitoring approach is right for your clinical journey.

The "Baseline" Sample: Don’t Miss the Window for MRD Tracking

If you are considering advanced minimal residual disease (MRD) monitoring for Multiple Myeloma, there is a critical first step for many technologies: The Baseline.

Why it’s essential:

Newer monitoring technologies work by identifying your cancer’s unique molecular "fingerprint." To track this fingerprint at ultra-sensitive levels later, the lab must first "map" it while your levels are still detectable (usually at diagnosis or before a new treatment).

Share this to your networks to help others learn about the importance of baselines 💡

In case you missed it last week 📰

The University of Waterloo recently published a news article on the development of EasyM, a blood based minimal residual disease (MRD) test for Multiple Myeloma (MM) 🩸

Key Takeaway Points:

- Sensitivity & Specificity: Research indicates that EasyM can detect the unique M-protein "fingerprint" even when traditional methods cannot.

- Observation Windows: In clinical evaluations, blood-based monitoring identified rising M-protein levels up to 11 months earlier than conventional methods.

- Accessibility: Following the Ministry of Health provisional license, this non-invasive MRD monitoring tool is available for clinical use in Canada.

Read the full article here: https://uwaterloo.ca/news/diagnosing-cancer-drop-blood